A new IADS report reveals how luxury's slowdown and a permanent shift to casual styles are forcing major retailers to pivot. The response: doubling down on athleisure, accessible price points, and in-store experiences to attract customers and sustain growth.
Quantum computing firm IonQ has moved to acquire SkyWater Technology, Skyloom Global, and Seed Innovations, aiming to create a comprehensive, end-to-end platform that controls hardware, networking, and software. This vertical integration strategy targets government and enterprise clients seeking secure, full-stack quantum solutions.
Netflix shares have tumbled from recent highs amid investor skepticism over a potential $72 billion acquisition. Despite the sell-off, some Wall Street firms are upgrading the stock, citing strong fundamentals and a historically attractive valuation.
Avidbank Holdings (AVBH) reported robust loan and deposit growth alongside an expanding net interest margin for Q4 2025, while management detailed plans to address a recent uptick in non-performing assets linked to specific construction and sponsor finance loans.
Citi analyst Geoff Meacham raised his price target on Bristol-Myers Squibb (BMY) to $60, citing a more favorable setup for the sector. The move comes as the drugmaker also announces a partnership with Microsoft to leverage AI for earlier lung cancer detection.
As cocoa futures pull back from historic highs, Morgan Stanley boosts its price target for snack giant Mondelez International, citing improved earnings visibility. The firm maintains an Overweight rating, highlighting the company's resilient financials and shareholder returns amidst lingering sales growth uncertainties.
ARK Invest CEO Cathie Wood argues the parabolic rise in gold, not artificial intelligence, represents the current asset bubble, pointing to its recent sharp correction as validation of her view while reaffirming her bullish stance on Bitcoin.
Bitcoin struggles to find a floor, trading near November lows as the nomination of Kevin Warsh for Fed Chair fails to spark a rally. Persistent outflows from US spot ETFs and a broader risk-off mood compound the pressure, raising fresh doubts about the cryptocurrency's 'digital gold' narrative.
A dual shift in U.S. sanctions and Venezuelan oil law is unlocking the country's vast reserves for American companies, marking a potential turning point after decades of nationalization and economic isolation.
A discounted cash flow analysis suggests Australis Oil & Gas (ASX:ATS) shares may be trading close to their intrinsic value. We examine the model's assumptions and the broader context for the energy junior.
After a November dip, Texas's upstream oil and gas sector added 2,000 jobs in December, contributing to the state's record-breaking employment figures and underscoring the industry's pivotal role in the Texan economy and tax base.
Porsche Automobil Holding (XTRA:PAH3) finds itself under the investor microscope following a turbulent month that saw its shares shed nearly 9%. While key valuation metrics scream 'undervalued', a deeper look reveals persistent losses and negative long-term returns, leaving analysts divided on its true worth.
As QuantumScape shares hover near $10, a stark divergence emerges between its discounted cash flow valuation and its price-to-book ratio. With the stock down year-to-date but up sharply over one year, investors are weighing the promise of solid-state batteries against execution risks and market volatility.
As interest rates retreat, income investors are revisiting blue-chip dividend stocks. Altria (MO), with its 7.1% yield and decades of payout growth, presents a compelling, if controversial, case for capital preservation and income generation.
The new year kicked off with significant personnel changes in the human resources executive suite, highlighting strategic expansions of roles and notable returns to former companies.
Investors face a classic choice between AbbVie's steady dividends and Abivax's high-risk, high-reward potential as both target lucrative immunology markets.
After the COVID-19 windfall subsided, Pfizer CEO Albert Bourla is steering the pharmaceutical giant into a high-stakes, $23 billion pivot to cancer research. Facing a looming patent cliff and plummeting vaccine revenue, Bourla is betting on scientific innovation to secure the company's future—and redefine cancer treatment.
Wix.com Ltd. has launched a major share repurchase program as its stock trades near multi-year lows. While analysts have trimmed price targets, many maintain bullish ratings, citing significant upside potential and a more resilient outlook for SaaS companies in the face of AI disruption.
As gold breaches historic price levels, retirees face critical decisions on how to integrate the precious metal into their portfolios. We examine the trade-offs between physical bars, coins, and ETFs in a transformed market.
Despite posting no revenue, Voltaic Strategic Resources (ASX:VSR) has seen its share price skyrocket 300% in the past year. We analyze whether its cash reserves can fuel further growth or if a reckoning is on the horizon.
